In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume ...

A stepped tariff schedule targets generics only, preserving existing treatment for patented and innovative drugs while signaling punitive intent for firms that do not invest in U.S. plant and ...

In today's Pharmaceutical Executive Daily, Novo Nordisk sues Eli Lilly over GLP-1 advertising it calls misleading, President Trump announces a phased tariff plan for imported generic drugs, and a new ...

EUA marks the first U.S. multiplex PCR capable of differential detection of HSV-1, HSV-2, VZV, and MPXV from a single specimen. Overlapping lesion morphology makes sequential single-pathogen testing ...

Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...

Litigation targets comparative efficacy messaging that allegedly pits Zepbound 10/15 mg against Wegovy 1.7/2.4 mg while omitting FDA-approved 7.2 mg Wegovy, complicating head-to-head implications.

Gerren McHam, vice president of Government and External Affairs, API Innovation Center, describes how China’s recent export control updates may introduce new vulnerabilities for ...

In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, a Pharmaceutical Executive commentary argues AI-driven patient support ...

Pharmaceutical Executive recently spoke with Nuvation Bio’s president, CEO, and founder David Hung. The growing biotech is ...

LillyDirect exemplifies DTP as a demand-unlocking commercial channel rather than a compliance tactic, with executives ...

A two-track structure combines AI-native target discovery and generative chemistry with formulation, CMC, regulatory strategy, tech transfer, scale-up, and commercial supply to shorten the molecule-to ...